S3. Rituximab for ANCA-associated vasculitides: The French experience-Reference-Cited by-同舟云学术

S3. Rituximab for ANCA-associated vasculitides: The French experience

Published:2013-04 Issue:4 Volume:42 Page:534-536
ISSN:0755-4982
Container-title:La Presse Médicale
language:en
Short-container-title:La Presse Médicale

Author:

Charles Pierre,Guillevin Loïc

Publisher

Elsevier BV

Subject

General Medicine

Reference14 articles.

1. Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapy;Specks;Arthritis Rheum,2001

2. Rituximab versus cyclophosphamide for ANCA-associated vasculitis;Stone;N Engl J Med,2010

3. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis;Jones;N Engl J Med,2010

4. Infliximab or rituximab for refractory Wegener's granulomatosis: long-term follow-up. A prospective randomised multicentre study on 17 patients;de Menthon;Clin Exp Rheumatol,2011

5. Adjunction of rituximab to steroids and immunosuppressants for refractory/relapsing Wegener's granulomatosis: a study on 8 patients;Brihaye;Clin Exp Rheumatol,2007

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Headaches and Vasculitis;Neurologic Clinics;2024-05

2. Systemic vasculitis and headache;Current Opinion in Neurology;2023-10-12

3. Adult and childhood vasculitis;Motor System Disorders, Part I: Normal Physiology and Function and Neuromuscular Disorders;2023

4. Experience with similar biologic rituximab in 77 patients of granulomatosis with polyangiitis—a real-life experience;Clinical Rheumatology;2020-07-12

5. Is rituximab “The Wonder Drug” for antineutrophil cytoplasmic antibodies-associated vasculitis?;Indian Journal of Rheumatology;2019